According to the document, the volume of production is planned to triple by 2026.

As for restrictions, the document cancels:

▪️ the ban on the collection of donated blood and the production of pharmaceutical products on its basis;
▪️ the restriction on conducting clinical trials of drugs on healthy volunteers;
▪️ the restriction on the production of medicines with the same composition by one manufacturer under different trade names.